cortisol suppression as clinical endpoint [Design Issues]

posted by nobody – 2014-09-12 18:00 (4300 d 11:40 ago) – Posting: # 13500
Views: 14,014

:-D

...on the other hand: Teva and others succeeded with BE data alone apparently, got some Risk Management Plan with suppression to be studied, iirc the Assessment Report. So apparently not really needed, this fancy cortisol thing.

Kindest regards, nobody

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
138 visitors (0 registered, 138 guests [including 32 identified bots]).
Forum time: 05:40 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5